Related Experiment Videos
Correlates of hepatitis C virus infections among injection drug users
D L Thomas1, D Vlahov, L Solomon
1Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Insights
Injection drug users face high hepatitis C virus (HCV) risk. Some users remain HCV-free despite exposure, a phenomenon requiring further study for immune response insights.
Area of Science:
- Hepatology
- Infectious Diseases
- Public Health
Background:
- Injection drug use is a primary risk factor for hepatitis C virus (HCV) infection.
- High HCV prevalence exists among specific injection drug user (IDU) demographics in Baltimore, including those who are Black, HIV-infected, and use cocaine.
- HCV infection is rapid, with 78% of participants testing positive within two years of initiating injection drug use.
Purpose of the Study:
- To investigate factors influencing HCV infection and seroprevalence in injection drug users.
- To explore the reasons behind HCV persistence in some individuals despite prolonged exposure.
- To understand the mechanisms of resistance to HCV infection in certain long-term IDUs.
Main Methods:
- Cross-sectional study of injection drug users in Baltimore, Maryland.
- Serological testing for anti-HCV antibodies.
- Detection of HCV RNA in serum samples.
- Analysis of demographic, behavioral, and socioeconomic factors.
Main Results:
- Prevalence of anti-HCV is higher in Black IDUs, those with HIV, and those with longer/more frequent injection histories, particularly cocaine use.
- HCV infection occurs rapidly after initiating injection drug use.
- Socioeconomic factors and sexual practices were not significantly related to anti-HCV prevalence.
- Some long-term IDUs remained anti-HCV negative, with some having detectable HCV RNA, indicating infection without antibody response.
Conclusions:
- The study highlights specific risk factors for HCV infection among IDUs.
- The mechanisms for the absence of anti-HCV response in some exposed individuals are unknown and warrant further investigation.
- Understanding these immune responses could inform strategies to combat persistent HCV infections.
- Early interventions targeting populations at risk for injection drug use are crucial for HCV prevention.
Abstract:
Injection drug users are at high risk for hepatitis C virus (HCV) infection. In Baltimore, Maryland, the prevalence of anti-HCV is greater among injection drug users who are black, human immunodeficiency virus (HIV) infected, have injected longer, have injected more frequently, and have injected cocaine than among other injection drug users. HCV infection occurs quickly after the initiation of injecting illicit drugs, with 78% of study participants anti-HCV positive after 2 years of injecting. The prevalence of anti-HCV among injection drug users does not appear to be related to socioeconomic factors or sexual practices. Some injection drug users remain free of anti-HCV even after years of injecting and serologic evidence of other bloodborne pathogens. Some of these injection drug users have HCV infection, demonstrated by HCV RNA in their sera. However, the basis for viral persistence in the absence of anti-HCV and for the absence of HCV infection in long-term drug users is not known. Further studies are indicated to determine the mechanism or mechanisms for the absence of anti-HCV in persons exposed to the virus, because the biologic basis for this condition may elucidate the elements missing in the immune response of the majority of HCV-exposed persons who acquire persistent infection. In addition, interventions to prevent HCV infections should be applied in populations at risk for injection drug use early or before drug use begins.